<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248989</url>
  </required_header>
  <id_info>
    <org_study_id>ERC-204</org_study_id>
    <nct_id>NCT00248989</nct_id>
  </id_info>
  <brief_title>Effect of DHEA on Skin Aging in Postmenopausal Women</brief_title>
  <official_title>Effect of DHEA on Skin Aging - Placebo-Controlled and Randomized Phase III Study in Postmenopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the response of skin parameters related to skin
      aging to the local action of DHEA in postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Humans, along with the others primates, are unique among animal species in having adrenals
      that secrete large amounts of the inactive precursor steroids dehydroepiandrosterone(DHEA)and
      especially its sulfate DHEA-S. The marked reduction in the formation of DHEA-S by the
      adrenals during aging results in a dramatic fall in the formation of androgens and estrogens
      in peripheral target tissues, a situation that has been proposed to be associated with
      age-related diseases including skin atrophy, insulin resistance and obesity. Moreover, much
      attention has been given to the benefits of DHEA administered to postmenopausal women,
      especially on the bone, skin, vagina and well being after oral as well as percutaneous
      administration of the precursor steroid.

      Therefore this study proposes to study the effect of 0.3% DHEA cream during a period of 12
      months administered twice daily to postmenopausal women. During the study several biological
      and clinical parameters will be evaluated. In summary, these include blood steroid levels,
      distribution of hormonal receptors in the skin, sebaceous gland activity, skin hydration,
      skin wrinkles and finally skin genomic evaluation.

      Subjects will be evaluated at specific time intervals for the above mentioned parameters as
      well as tolerability and adverse reactions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2004</start_date>
  <completion_date type="Actual">November 13, 2008</completion_date>
  <primary_completion_date type="Actual">November 24, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of local activity of DHEA for a 12 months period in parameters such as wrinkles, sebaceous gland activity, changes in skin morphology and other physical skin parameters.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of tolerance to local skin application of DHEA for a 12 months period and potential beneficial effects on quality of life including sexual life.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Skin Aging</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DHEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dehydroepiandrosterone</intervention_name>
    <description>3.0 ml of 0.3% DHEA cream applied on the skin twice daily.</description>
    <arm_group_label>DHEA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>3.0 ml of placebo cream applied on the skin twice daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy postmenopausal women who have taken hormonal replacement therapy for at least
             two years but not during the last 6 months prior to the study.

          -  Aged between 60 and 65.

        Exclusion Criteria:

          -  Significant dermatologic, metabolic and endocrine disease.

          -  Diagnosis of cancer or history of hormone-dependant cancer.

          -  Over exposure to sun or tanning session during the previous two months.

          -  Narcotic addiction, alcoholism or smoking.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonello Cusan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUL Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernand Labrie, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHUL Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique des Traitements Hormonaux- CHUL Research Center</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharrière O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4279-84.</citation>
    <PMID>10760294</PMID>
  </reference>
  <reference>
    <citation>Bardon S, Vignon F, Chalbos D, Rochefort H. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J Clin Endocrinol Metab. 1985 Apr;60(4):692-7.</citation>
    <PMID>3972969</PMID>
  </reference>
  <reference>
    <citation>Bélanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL, Labrie F. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab. 1994 Oct;79(4):1086-90.</citation>
    <PMID>7962278</PMID>
  </reference>
  <reference>
    <citation>Benz DJ, Haussler MR, Thomas MA, Speelman B, Komm BS. High-affinity androgen binding and androgenic regulation of alpha 1(I)-procollagen and transforming growth factor-beta steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells. Endocrinology. 1991 Jun;128(6):2723-30.</citation>
    <PMID>2036957</PMID>
  </reference>
  <reference>
    <citation>Burger HG, Hailes J, Menelaus M, Nelson J, Hudson B, Balazs N. The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas. 1984 Dec;6(4):351-8.</citation>
    <PMID>6442755</PMID>
  </reference>
  <reference>
    <citation>Casson PR, Andersen RN, Herrod HG, Stentz FB, Straughn AB, Abraham GE, Buster JE. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol. 1993 Dec;169(6):1536-9.</citation>
    <PMID>8267058</PMID>
  </reference>
  <reference>
    <citation>Chesnut CH 3rd, Ivey JL, Gruber HE, Matthews M, Nelp WB, Sisom K, Baylink DJ. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action. Metabolism. 1983 Jun;32(6):571-80.</citation>
    <PMID>6341772</PMID>
  </reference>
  <reference>
    <citation>Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995 Jun 15;332(24):1589-93.</citation>
    <PMID>7753136</PMID>
  </reference>
  <reference>
    <citation>Coleman DL, Leiter EH, Schwizer RW. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes. 1982 Sep;31(9):830-3.</citation>
    <PMID>6219024</PMID>
  </reference>
  <reference>
    <citation>Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995 Apr;21(3):227-36.</citation>
    <PMID>7616872</PMID>
  </reference>
  <reference>
    <citation>DeFazio J, Meldrum DR, Winer JH, Judd HL. Direct action of androgen on hot flushes in the human male. Maturitas. 1984 Jul;6(1):3-8.</citation>
    <PMID>6472125</PMID>
  </reference>
  <reference>
    <citation>Diamond P, Cusan L, Gomez JL, Bélanger A, Labrie F. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol. 1996 Sep;150 Suppl:S43-50.</citation>
    <PMID>8943786</PMID>
  </reference>
  <reference>
    <citation>El-Alfy M, Luu-The V, Huang XF, Berger L, Labrie F, Pelletier G. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology. 1999 Mar;140(3):1481-91.</citation>
    <PMID>10067877</PMID>
  </reference>
  <reference>
    <citation>El-Alfy M, Pelletier G, Hermo LS, Labrie F. Unique features of the basal cells of human prostate epithelium. Microsc Res Tech. 2000 Dec 1;51(5):436-46.</citation>
    <PMID>11074614</PMID>
  </reference>
  <reference>
    <citation>Gordon GB, Shantz LM, Talalay P. Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone. Adv Enzyme Regul. 1987;26:355-82. Review.</citation>
    <PMID>2960133</PMID>
  </reference>
  <reference>
    <citation>Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973 Feb;36(2):207-14.</citation>
    <PMID>4688315</PMID>
  </reference>
  <reference>
    <citation>Henderson E, Yang JY, Schwartz A. Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication. AIDS Res Hum Retroviruses. 1992 May;8(5):625-31.</citation>
    <PMID>1381206</PMID>
  </reference>
  <reference>
    <citation>HENNEMAN PH, WALLACH S. A review of the prolonged use of estrogens and androgens in postmenopausal and senile osteoporosis. AMA Arch Intern Med. 1957 Nov;100(5):715-23.</citation>
    <PMID>13468816</PMID>
  </reference>
  <reference>
    <citation>Johnston CC Jr, Epstein S. Clinical, biochemical, radiographic, epidemiologic, and economic features of osteoporosis. Orthop Clin North Am. 1981 Jul;12(3):559-69.</citation>
    <PMID>7290587</PMID>
  </reference>
  <reference>
    <citation>Johnston CC Jr, Hui SL, Witt RM, Appledorn R, Baker RS, Longcope C. Early menopausal changes in bone mass and sex steroids. J Clin Endocrinol Metab. 1985 Nov;61(5):905-11.</citation>
    <PMID>3930555</PMID>
  </reference>
  <reference>
    <citation>Kapur SP, Reddi AH. Influence of testosterone and dihydrotestosterone on bone-matrix induced endochondral bone formation. Calcif Tissue Int. 1989 Feb;44(2):108-13.</citation>
    <PMID>2492887</PMID>
  </reference>
  <reference>
    <citation>Labrie C, Belanger A, Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology. 1988 Sep;123(3):1412-7.</citation>
    <PMID>2969802</PMID>
  </reference>
  <reference>
    <citation>Labrie F. Intracrinology. Mol Cell Endocrinol. 1991 Jul;78(3):C113-8. Review.</citation>
    <PMID>1838082</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Bélanger A, Cusan L, Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab. 1997 Aug;82(8):2403-9.</citation>
    <PMID>9253308</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab. 1997 Aug;82(8):2396-402.</citation>
    <PMID>9253307</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Bélanger A, Simard J, Van Luu-The, Labrie C. DHEA and peripheral androgen and estrogen formation: intracinology. Ann N Y Acad Sci. 1995 Dec 29;774:16-28. Review.</citation>
    <PMID>8597456</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab. 1997 Oct;82(10):3498-505.</citation>
    <PMID>9329392</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX, Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. 2003 Apr;24(2):152-82. Review.</citation>
    <PMID>12700178</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, Bélanger A. The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids. 1997 Jan;62(1):148-58.</citation>
    <PMID>9029730</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Luu-The V, Lin SX, Simard J, Labrie C. Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol Metab. 2000 Dec;11(10):421-7. Review.</citation>
    <PMID>11091120</PMID>
  </reference>
  <reference>
    <citation>Labrie F, Simard J, Luu-The V, Bélanger A, Pelletier G, Morel Y, Mebarki F, Sanchez R, Durocher F, Turgeon C, Labrie Y, Rhéaume E, Labrie C, Lachance Y. The 3b-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3b-HSD congenital deficiency. In: Signal Transduction in Testicular Cells. Ernst Schering Research Foundation Workshop. Hansson V, Levy FO, Taskén K (eds), Berlin, Heidelberg, New York, Springer-Verlag, Vol. Suppl. 2: pp. 185-218, 1996.</citation>
  </reference>
  <reference>
    <citation>Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA. 1983 Apr 22-29;249(16):2195-8.</citation>
    <PMID>6834616</PMID>
  </reference>
  <reference>
    <citation>Li S, Yan X, Bélanger A, Labrie F. Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res Treat. 1994 Feb;29(2):203-17.</citation>
    <PMID>8012037</PMID>
  </reference>
  <reference>
    <citation>MacEwen EG, Kurzman ID. Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA). J Nutr. 1991 Nov;121(11 Suppl):S51-5. doi: 10.1093/jn/121.suppl_11.S51. Review.</citation>
    <PMID>1834816</PMID>
  </reference>
  <reference>
    <citation>Mazess RB. On aging bone loss. Clin Orthop Relat Res. 1982 May;(165):239-52.</citation>
    <PMID>7075066</PMID>
  </reference>
  <reference>
    <citation>MIGEON CJ, KELLER AR, LAWRENCE B, SHEPARD TH 2nd. Dehydroepiandrosterone and androsterone levels in human plasma: effect of age and sex; day-to-day and diurnal variations. J Clin Endocrinol Metab. 1957 Sep;17(9):1051-62.</citation>
    <PMID>13463066</PMID>
  </reference>
  <reference>
    <citation>Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 1994 Jun;78(6):1360-7. Erratum in: J Clin Endocrinol Metab 1995 Sep;80(9):2799.</citation>
    <PMID>7515387</PMID>
  </reference>
  <reference>
    <citation>Need AG, Horowitz M, Bridges A, Morris HA, Nordin BE. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women. Arch Intern Med. 1989 Jan;149(1):57-60.</citation>
    <PMID>2912415</PMID>
  </reference>
  <reference>
    <citation>Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab. 1988 Jan;66(1):57-61.</citation>
    <PMID>2961787</PMID>
  </reference>
  <reference>
    <citation>Notelovitz M, Watts N, Timmons C, Addison A, Wiita B, Downey L. Effects of estrogen plus low dose androgen vs estrogen alone on menopausal symptoms in oophorectomized/hysterectomized. North Am. Menopause Soc., Montreal 1991, 101.</citation>
  </reference>
  <reference>
    <citation>Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984 Sep;59(3):551-5.</citation>
    <PMID>6235241</PMID>
  </reference>
  <reference>
    <citation>Pye JK, Mansel RE, Hughes LE. Clinical experience of drug treatments for mastalgia. Lancet. 1985 Aug 17;2(8451):373-7.</citation>
    <PMID>2862523</PMID>
  </reference>
  <reference>
    <citation>Rasmussen KR, Arrowood MJ, Healey MC. Effectiveness of dehydroepiandrosterone in reduction of cryptosporidial activity in immunosuppressed rats. Antimicrob Agents Chemother. 1992 Jan;36(1):220-2.</citation>
    <PMID>1534212</PMID>
  </reference>
  <reference>
    <citation>Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ 3rd. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981 Feb;67(2):328-35.</citation>
    <PMID>7462421</PMID>
  </reference>
  <reference>
    <citation>Savvas M, Studd JW, Fogelman I, Dooley M, Montgomery J, Murby B. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. BMJ. 1988 Jul 30;297(6644):331-3.</citation>
    <PMID>3137998</PMID>
  </reference>
  <reference>
    <citation>Schriock ED, Buffington CK, Hubert GD, Kurtz BR, Kitabchi AE, Buster JE, Givens JR. Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab. 1988 Jun;66(6):1329-31.</citation>
    <PMID>2967305</PMID>
  </reference>
  <reference>
    <citation>Schwartz AG, Pashko L, Whitcomb JM. Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol. 1986;14(3):357-62. Review.</citation>
    <PMID>3024302</PMID>
  </reference>
  <reference>
    <citation>Sherwin BB. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord. 1988 Mar-Apr;14(2):177-87.</citation>
    <PMID>2966832</PMID>
  </reference>
  <reference>
    <citation>Sherwin BB, Gelfand MM. Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause. Am J Obstet Gynecol. 1984 Mar 1;148(5):552-7.</citation>
    <PMID>6367474</PMID>
  </reference>
  <reference>
    <citation>Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol. 1985 Jan 15;151(2):153-60.</citation>
    <PMID>3881960</PMID>
  </reference>
  <reference>
    <citation>Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med. 1987 Jul-Aug;49(4):397-409.</citation>
    <PMID>3615768</PMID>
  </reference>
  <reference>
    <citation>Sourla A, Richard V, Labrie F, Labrie C. Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J Endocrinol. 2000 Aug;166(2):455-62.</citation>
    <PMID>10927635</PMID>
  </reference>
  <reference>
    <citation>Steinberg KK, Freni-Titulaer LW, DePuey EG, Miller DT, Sgoutas DS, Coralli CH, Phillips DL, Rogers TN, Clark RV. Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab. 1989 Sep;69(3):533-9.</citation>
    <PMID>2527242</PMID>
  </reference>
  <reference>
    <citation>Studd J W, Collins W P, Chakravarti S, Newton J R, Oram D, Parsons A. Estradiol and testosterone implants in treatment of psochosexual problems in postmenopausal women. Br. J. Obstet. Gynecol. 84: 314-315, 1987.</citation>
  </reference>
  <reference>
    <citation>Suzuki T, Suzuki N, Daynes RA, Engleman EG. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol. 1991 Nov;61(2 Pt 1):202-11.</citation>
    <PMID>1833106</PMID>
  </reference>
  <reference>
    <citation>Tchernof A, Després JP, Bélanger A, Dupont A, Prud'homme D, Moorjani S, Lupien PJ, Labrie F. Reduced testosterone and adrenal C19 steroid levels in obese men. Metabolism. 1995 Apr;44(4):513-9.</citation>
    <PMID>7723675</PMID>
  </reference>
  <reference>
    <citation>Vermeulen A, Deslypere JP, Schelfhout W, Verdonck L, Rubens R. Adrenocortical function in old age: response to acute adrenocorticotropin stimulation. J Clin Endocrinol Metab. 1982 Jan;54(1):187-91.</citation>
    <PMID>6274897</PMID>
  </reference>
  <reference>
    <citation>Vermeulen A, Verdonck L. Radioimmunoassay of 17beta-hydroxy-5alpha-androstan-3-one, 4-androstene-3,17-dione, dehydroepiandrosterone, 17-hydroxyprogesterone and progesterone and its application to the human male plasma. J Steroid Biochem. 1976 Jan;7(1):1-10.</citation>
    <PMID>178963</PMID>
  </reference>
  <reference>
    <citation>Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab. 1995 Apr;80(4):1429-30.</citation>
    <PMID>7714119</PMID>
  </reference>
  <results_reference>
    <citation>Labrie F, Cusan L, Gomez JL, Martel C, Bérubé R, Bélanger P, Chaussade V, Deloche C, Leclaire J. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol. 2008 May;110(1-2):1-9. doi: 10.1016/j.jsbmb.2008.02.003. Epub 2008 Feb 14.</citation>
    <PMID>18359622</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2005</study_first_submitted>
  <study_first_submitted_qc>November 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2005</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin aging</keyword>
  <keyword>Menopausal symptoms</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

